Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 575

Sort by

Sort Order Select

Journal Articles

Deletion 17p: a matter of size and number?

Sonja Zweegman, Niels W. C. J. van de Donk

Blood (2021) 137 (9): 1135–1136.

https://doi.org/10.1182/blood.2020009102

Published: 2021

Journal Articles

Infectious mononucleosis affecting sinonasal mucosa

Elham Vali Betts, Regina Gandour-Edwards

Blood (2019) 134 (22): 1996.

https://doi.org/10.1182/blood.2019002978

Published: 2019

Journal Articles

Kmt2c Limits the Self-Renewal Capacity of Multiply Divided HSCs By Promoting Sensitivity to Interleukin-1

Ran Chen, PhD, Theresa O. Owuor, PhD, Riddhi M Patel, BS, Emily Casey, Jeffrey A. Magee, MD PhD

Blood (2019) 134 (Supplement_1): 3711.

https://doi.org/10.1182/blood-2019-126229

Published: 2019

Journal Articles

Transcriptomic Profile of Bone Marrow-Derived Mesenchymal Stromal Cells of Pediatric Pre-B Acute Lymphoblastic Leukemia Patients and Healthy Donors after Interaction with Leukemic Cells

Tuba Özdemi̇r Sanci, MSc, Hilal Özdağ, PhD, Yasin Köksal, MSc, Seda Tasır Yılmaz, MSc, Husniye Nese Yarali, MD, Namik Yasar Özbek, MD, Habibe Meltem Özgüner, MD

Blood (2019) 134 (Supplement_1): 3957.

https://doi.org/10.1182/blood-2019-128282

Published: 2019

Journal Articles

First-in-Human Study of Abbv-621, a TRAIL Receptor Agonist Fusion Protein, in Patients (Pts) with Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML) and Diffuse Large B-Cell Lymphoma (DLBCL)

Maja J.A. de Jonge, MD, Benedito A. Carneiro, MD, Lot Devriese, MD PhD, Toshihiko Doi, MD PhD, Sudhir Penugonda, MD MPH, Adam M. Petrich, MD, Silpa Nuthalapati, PhD, Monica Motwani, PhD, Dimple A. Modi, PhD, Yu-Wei Chang, PhD, Emiliano Calvo, MD PhD, Victor Moreno, MD PhD

Blood (2019) 134 (Supplement_1): 3924.

https://doi.org/10.1182/blood-2019-129783

Published: 2019

Journal Articles

Inhibiting Mitochondria Function By Bcl-2 Inhibitor Venetoclax and Complex I Inhibitor Iacs-010759 Eliminate Leukemia Cells in Pre-Clinical AML Models

Qi Zhang, PhD, Alessia Lodi, PhD, Shannon Renee Sweeney, PhD, Lina Han, PhD, Tianyu Cai, PhD, Vinitha Mary Kuruvilla, MSc, Antonio Cavazos, Helen Ma, MS, Yoko Tabe, MD PhD, Joseph R Marszalek, PhD, Stefano Tiziani, PhD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3927.

https://doi.org/10.1182/blood-2019-124494

Published: 2019

Journal Articles

Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia

Christoph Kornauth, Charles Herbaux, MD MSc, Bernd Boidol, PhD, Chantal Guillemette, Patrick Caron, Stéphanie Poulain, MD PhD, Olivier Tournilhac, Marius E Mayerhoefer, Ulrich Jaeger, MD, Stefan Kubicek, Matthew S. Davids, MD, Philipp Bernhard Staber, MD PhD

Blood (2019) 134 (Supplement_1): 3965.

https://doi.org/10.1182/blood-2019-124392

Published: 2019

Journal Articles

Efficient Elimination of Acute Myeloid Leukemia Cells through Inhibition of KDM4A in Combination with PARP Inhibition

Laura Monaghan, BSc, Matthew Edward Massett, MSc, BSc, Roderick P Bunschoten, BSc, Petrisor Alin Pirvan, MSc, BSc, Alex Hoose, Bsc, PhD, Taeju Park, BSc, Joana Bittencourt-Silvestre, BSc, MSc, Robert M J Liskamp, BSc, PhD, Heather G Jørgensen, Xu Huang, BSc, PhD

Blood (2019) 134 (Supplement_1): 3756.

https://doi.org/10.1182/blood-2019-125355

Published: 2019

Journal Articles

Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR

Philipp Bernhard Staber, MD PhD, Christoph Kornauth, Ines Garces de los Fayos Alonso, Wilhelm Woessmann, MD, Wolfram Klapper, Sabine Lagger, Ana-Iris Schiefer, Cathrin Skrabs, Olaf Merkel, PhD, Marius E Mayerhoefer, Richard Greil, MD, Ingrid Simonitsch-Klupp, MD, Lukas Kenner, MD, Ulrich Jaeger, MD

Blood (2019) 134 (Supplement_1): 4037.

https://doi.org/10.1182/blood-2019-129955

Published: 2019

Journal Articles

Metabolic Tumor Volume for Early Response Assessment in Early-Stage Unfavorable Hodgkin Lymphoma Treated with Nivolumab in the GHSG Nivahl Phase II Trial

Conrad-Amadeus Voltin, Jasmin Mettler, MD, Horst Mueller, PhD, Michael Fuchs, MD, Christian Baues, MD, Markus Dietlein, MD, Andreas Engert, MD, Peter Borchmann, MD PhD, Carsten Kobe, Paul J Bröckelmann, MD

Blood (2019) 134 (Supplement_1): 4020.

https://doi.org/10.1182/blood-2019-123641

Published: 2019

Journal Articles

TJC4, a Differentiated Anti-CD47 Antibody with Novel Epitope and RBC Sparing Properties

Zhen Meng, PhD, Zhengyi Wang, PhD, Bingshi Guo, PhD, Wei Cao, PhD, Huaqiong Shen, MD PhD

Blood (2019) 134 (Supplement_1): 4063.

https://doi.org/10.1182/blood-2019-122793

Published: 2019

Journal Articles

UAF1 DNA Binding Activity Is Critical for RAD51-Mediated Homologous DNA Pairing

Fengshan Liang, PhD, Adam S Miller, PhD, Carolilne Tang, Patrick Sung, PhD, Gary M. Kupfer, MD

Blood (2019) 134 (Supplement_1): 2497.

https://doi.org/10.1182/blood-2019-130435

Published: 2019

Journal Articles

A Transcriptomic Continuum of Differentiation Arrest in Acute Leukemia

Jonathan Bond, Aleksandra Krzywon, Ludovic Lhermitte, MD PhD, Christophe Roumier, PharmD, Anne Roggy, Mohamed Belhocine, PhD MSc, BSc, Alexander Kheirallah, Patrick Villarese, PhD, Guillaume Hypolite, Francine Garnache-Ottou, D.Pharm PhD, Herve Dombret, MD PhD, Nicolas Boissel, MD PhD, Claude Preudhomme, PharmD, PhD, Vahid Asnafi, MD PhD, Elisa Laurenti, PhD, Elizabeth Macintyre, PhDMD

Blood (2019) 134 (Supplement_1): 2511.

https://doi.org/10.1182/blood-2019-125902

Published: 2019

Journal Articles

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

Scott R. Goldsmith, MD, Sana Saif Ur Rehman, MD, Cara Lunn Shirai, PhD, Ravi Vij, MBBS, John F. DiPersio, MD PhD

Blood (2019) 134 (Supplement_1): 2325.

https://doi.org/10.1182/blood-2019-124176

Published: 2019

Journal Articles

Nascent Transcript and Single Cell Rnaseq Analysis Defines the Mechanism of Action of the LSD1 Inhibitor INCB059872 in Myeloid Leukemia

Gretchen Johnston, Haley E. Ramsey, PhDMSc, Kristy Stengel, PhD, Shilpa Sampathi, PhD, Pankaj Acharya, PhD, Maria Arrate, MSc, Matthew C. Stubbs, PhD, Timothy Burn, PhD, Scott Hiebert, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 2509.

https://doi.org/10.1182/blood-2019-130458

Published: 2019

Journal Articles

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines

Gro Elise Rødland, PhD, Katrine Melhus, Roman Generalov, Sania Gilani, Francesco Bertoni, MD, Jostein Dahle, PhD, Randi Syljuåsen, PhD, Sebastian Patzke, PhD

Blood (2019) 134 (Supplement_1): 2574.

https://doi.org/10.1182/blood-2019-123287

Published: 2019

Journal Articles

EZH2 Gain-of-Function Mutations Generate a Lymphoma-Permissive Immune Niche

Wendy Béguelin, PhD, Matthew R Teater, PhD, Cem Meydan, PhD, Jude M Phillip, PhD, Ari Melnick, MD

Blood (2019) 134 (Supplement_1): 2768.

https://doi.org/10.1182/blood-2019-132263

Published: 2019

Journal Articles

Interaction of Mantle Cell Lymphoma with the Microenvironment Induces Phospho Akt-Mediated Resistance Against BTK Inhibition and Can be Overcome By Co-Treatment with a Specific Akt Inhibitor (MK-2206)

Elisabeth Silkenstedt, MD, Claudia Schwandner, Johanna Deuss, Natalie Mack, Yvonne Zimmermann, Martin Dreyling, MD

Blood (2019) 134 (Supplement_1): 2802.

https://doi.org/10.1182/blood-2019-128782

Published: 2019

Journal Articles

Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features

Yasunobu Nagata, MD PhD, Hideki Makishima, MD PhD, Cassandra M Kerr, MS, Bhumika J. Patel, MD, Hassan Awada, Vera Adema, PhD, Valeria Visconte, PhD, Sudipto Mukherjee, MD PhD MPH, Thomas Laframboise, PhD, Aziz Nazha, MD, Tomas Radivoyevitch, PhD, Mikkael A. Sekeres, MD MS, Seishi Ogawa, MD PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 2992.

https://doi.org/10.1182/blood-2019-128893

Published: 2019

Journal Articles

Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Final Results from the Phase IIIb GREEN Safety Study with a Focus on Efficacy

Stephan Stilgenbauer, MD, Francesc Bosch, MD PhD, Véronique Leblond, MD PhD, Osman Ilhan, MD, Jens Kisro, Béatrice Mahé, MD, Eva Mikuskova, MD PhD, Dzhelil Osmanov, MD, Gianluigi Reda, MD, Eugen Tausch, Marcin Wójtowicz, MD PhD, Thomas Perretti, MD MSc, Marlies EHM Van Hoef, MD PhD MBA, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 3035.

https://doi.org/10.1182/blood-2019-123419

Published: 2019

NARROW

Deletion 17p: a matter of size and number?

Infectious mononucleosis affecting sinonasal mucosa

Kmt2c Limits the Self-Renewal Capacity of Multiply Divided HSCs By Promoting Sensitivity to Interleukin-1

Transcriptomic Profile of Bone Marrow-Derived Mesenchymal Stromal Cells of Pediatric Pre-B Acute Lymphoblastic Leukemia Patients and Healthy Donors after Interaction with Leukemic Cells

First-in-Human Study of Abbv-621, a TRAIL Receptor Agonist Fusion Protein, in Patients (Pts) with Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML) and Diffuse Large B-Cell Lymphoma (DLBCL)

Inhibiting Mitochondria Function By Bcl-2 Inhibitor Venetoclax and Complex I Inhibitor Iacs-010759 Eliminate Leukemia Cells in Pre-Clinical AML Models

Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia

Efficient Elimination of Acute Myeloid Leukemia Cells through Inhibition of KDM4A in Combination with PARP Inhibition

Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR

Metabolic Tumor Volume for Early Response Assessment in Early-Stage Unfavorable Hodgkin Lymphoma Treated with Nivolumab in the GHSG Nivahl Phase II Trial

TJC4, a Differentiated Anti-CD47 Antibody with Novel Epitope and RBC Sparing Properties

UAF1 DNA Binding Activity Is Critical for RAD51-Mediated Homologous DNA Pairing

A Transcriptomic Continuum of Differentiation Arrest in Acute Leukemia

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

Nascent Transcript and Single Cell Rnaseq Analysis Defines the Mechanism of Action of the LSD1 Inhibitor INCB059872 in Myeloid Leukemia

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines

EZH2 Gain-of-Function Mutations Generate a Lymphoma-Permissive Immune Niche

Interaction of Mantle Cell Lymphoma with the Microenvironment Induces Phospho Akt-Mediated Resistance Against BTK Inhibition and Can be Overcome By Co-Treatment with a Specific Akt Inhibitor (MK-2206)

Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features

Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Final Results from the Phase IIIb GREEN Safety Study with a Focus on Efficacy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only